NHS England/NICE Consultation Could Spell Market Access Complications
Executive Summary
Companies with innovative and expensive drugs may face additional hurdles to get their products to the market in England, according to a consultation from NICE, England's health technology appraisal institute, and NHS England.
You may also be interested in...
UK Report Casts Doubt Over Use Of QALYs When Appraising Ultra Orphans
Office of Health Economics suggests additional criteria could include social preferences on treating patients with very rare diseases, impact beyond direct health benefits, or adjustments for low patient numbers.
BIA Says NHS Funding Changes Would Jeopardize Life Science Sector, As UK PM Announces ‘Hard’ Brexit
As prime minister Theresa May confirms that the UK is to leave the EU single market, the BioIndustry Association has warned that proposals by NICE and NHS England to change funding arrangements for innovative drugs risks impairing the competitiveness of the UK life sciences sector.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.